# OnCo record nci-match (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nci-match/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nci-match", "NCT02465060" ;
  schema:name "NCI-MATCH (EAY131)"@en ;
  schema:alternateName "NCI MATCH"@en, "Molecular Analysis for Therapy Choice"@en, "EAY131"@en, "MATCH trial"@en ;
  schema:description "NCI-MATCH was the largest trial to sequence tumours from thousands of patients across the United States and give each a drug matched to the mutation rather than to the organ. It proved the system could work at national scale, found real activity for a handful of matches, and showed that most single drugs given for a single mutation do little."@en ;
  schema:url <https://onco.cc/trials/nci-match/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02465060>, <https://www.cancer.gov/about-cancer/treatment/clinical-trials/nci-supported/nci-match>, <https://doi.org/10.1200/JCO.19.03010>, <https://doi.org/10.1200/JCO.20.00762>, <https://doi.org/10.1200/JCO.19.00818>, <https://doi.org/10.1038/s41591-023-02379-4>, <https://doi.org/10.1158/1078-0432.CCR-23-0983> ;
  onco:status "active" ;
  onco:tag "precision-medicine" ;
  onco:phase "platform" ;
  schema:startDate "2015-08-17" ;
  onco:cancers <https://onco.cc/terms/rare-cancers/> ;
  onco:technologies <https://onco.cc/technologies/cgp/>, <https://onco.cc/technologies/ngs-bioinformatics-software/>, <https://onco.cc/technologies/variant-knowledgebases/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/dabrafenib/>, <https://onco.cc/drugs/trametinib/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/trastuzumab-emtansine/>, <https://onco.cc/drugs/capivasertib/>, <https://onco.cc/drugs/copanlisib/>, <https://onco.cc/drugs/palbociclib/>, <https://onco.cc/drugs/sunitinib/>, <https://onco.cc/drugs/binimetinib/>, <https://onco.cc/drugs/afatinib/>, <https://onco.cc/drugs/osimertinib/>, <https://onco.cc/drugs/crizotinib/>, <https://onco.cc/drugs/larotrectinib/>, <https://onco.cc/drugs/adavosertib/> ;
  onco:companies <https://onco.cc/companies/ecog-acrin/> ;
  onco:institutions <https://onco.cc/institutions/nci/>, <https://onco.cc/institutions/frederick-national-lab/>, <https://onco.cc/institutions/md-anderson/>, <https://onco.cc/institutions/mgh/>, <https://onco.cc/institutions/yale-cancer-center/> ;
  onco:terms <https://onco.cc/terms/master-protocol/>, <https://onco.cc/terms/basket-umbrella-platform/>, <https://onco.cc/terms/tumour-agnostic/> ;
  onco:trials <https://onco.cc/trials/combomatch/>, <https://onco.cc/trials/myelomatch/>, <https://onco.cc/trials/pediatric-match/> ;
  onco:people <https://onco.cc/people/keith-flaherty/>, <https://onco.cc/people/peter-odwyer/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-rare-cancers/>, <https://onco.cc/bottlenecks/b-trial-design/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-o-dwyer-nat-med/>, <https://onco.cc/key-papers/paper-zhou-clin-cancer-res/>, <https://onco.cc/key-papers/paper-azad-j-clin-oncol/>, <https://onco.cc/key-papers/paper-flaherty-j-clin-oncol/>, <https://onco.cc/key-papers/paper-salama-j-clin-oncol/> .